BIONET Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	18.4yrs

Actualizaciones recientes de la dirección

Recent updates

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Apr 10

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

Feb 10

CEO

BIONET no tiene CEO, o no tenemos datos al respecto.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shao-Hua Huang	Independent Director	18yrs	sin datos	0.026% NT$ 1.2m
John Wagner	Member of Advisory Board	no data	sin datos	sin datos
Wen Yan	Independent Director	18.4yrs	sin datos	sin datos
Zheng Huang	Director	19.8yrs	sin datos	2.34% NT$ 110.0m
Cheng-Hsian Coi	Director	17.1yrs	sin datos	4.07% NT$ 191.1m
Wen Zhang	Director	21.6yrs	sin datos	1.9% NT$ 89.4m
Cui Zhang	Supervisor	24.3yrs	sin datos	sin datos
Zhao Fen Zhang	Supervisor	17.1yrs	sin datos	sin datos
Han Zhang	Director	18.4yrs	sin datos	sin datos
Shi Liang	Director	10.7yrs	sin datos	0.51% NT$ 23.9m
Cheng-Hsien Tsai	Chairman of the Board	no data	sin datos	sin datos
Han Tung Chang	Director	no data	sin datos	sin datos

18.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 1784 son experimentados ( 18.4 años antigüedad media).

BIONET Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

BIONET Corp., Annual General Meeting, Jun 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.37 in 3Q 2023)

Now 23% overvalued after recent price rise

Upcoming dividend of NT$0.71 per share

Second quarter 2024 earnings released: EPS: NT$0.35 (vs NT$0.67 in 2Q 2023)

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

First quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.49 in 1Q 2023)

Investor sentiment improves as stock rises 18%

BIONET Corp., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: NT$1.67 (vs NT$0.80 in FY 2022)

Third quarter 2023 earnings released: EPS: NT$0.40 (vs NT$0.34 in 3Q 2022)

Upcoming dividend of NT$0.70 per share at 1.0% yield

Second quarter 2023 earnings released: EPS: NT$0.67 (vs NT$0.15 in 2Q 2022)

New major risk - Share price stability

Less than half of directors are independent

Upcoming dividend of NT$0.49 per share

Second quarter 2022 earnings released: EPS: NT$0.15 (vs NT$0.25 in 2Q 2021)

First quarter 2022 earnings released: EPS: NT$0.10 (vs NT$0.25 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$0.56 (vs NT$0.27 in FY 2020)

Third quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.033 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.003 loss in 2Q 2020)

Upcoming dividend of NT$0.18 per share

First quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.11 in 1Q 2020)

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Full year 2020 earnings released: EPS NT$0.27 (vs NT$0.14 in FY 2019)

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

New 90-day low: NT$35.85

New 90-day high: NT$42.95

Third quarter 2020 earnings released: EPS NT$0.03

New 90-day low: NT$38.35

First half earnings released

CEO

Miembros de la Junta

Permanencia media

Promedio de edad